Subgroup analyses from READY: Real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC)

被引：2

作者：

Bracarda, Sergio ^{[1
]}

Antonuzzo, Lorenzo ^{[2
]}

Maruzzo, Marco ^{[3
]}

Santini, Daniele ^{[4
]}

Tambaro, Rosa ^{[5
]}

Buti, Sebastiano ^{[6
]}

Carrozza, Francesco ^{[7
,8
]}

Calabro, Fabio

Di Lorenzo, Giuseppe ^{[9
]}

Fornarini, Giuseppe ^{[10
]}

Iacovelli, Roberto ^{[11
]}

Cullura, Daniela ^{[12
]}

Messina, Carlo ^{[13
]}

Cerbone, Linda ^{[14
]}

Fazzi, Gennaro ^{[15
]}

Venturini, Filippo ^{[15
]}

Colasanto, Raffaele ^{[15
]}

Necchi, Andrea ^{[16
]}

De Giorgi, Ugo ^{[17
]}

机构：

[1] Azienda Osped Santa Maria, Terni, Italy

[2] Azienda Osped Univ Careggi, Florence, Italy

[3] IOV IRCCS, Ist Oncol Veneto, Padua, Italy

[4] Univ Sapienza Polo Pontino, Rome, Italy

[5] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[6] Univ Parma, Parma, Italy

[7] AUSL Romagna, Ravenna, Italy

[8] IFO Ist Regina Elena, Rome, Italy

[9] ASL SALERNO PO A Tortora, Pagani, Italy

[10] IRCCS Osped Policlin San Martino, Genoa, Italy

[11] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[12] Ist Europeo Oncol IEO, Milan, Italy

[13] Osped ARNAS Civ, Palermo, Italy

[14] Azienda Osped San Camillo Forlanini, Rome, Italy

[15] Merck Serono SPA, Merck KGaA, Rome, Italy

[16] IRCCS San Raffaele Hosp & Sci Inst, Milan, Italy

[17] IRCCS, Ist Romagnolo Studio Tumori IRST Dino Amadori, Meldola, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.4_suppl.558

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：558 / 558

页数：1

共 50 条

[41] SPADE: Design of a real-world observational study of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (UC) in the Asia-Pacific (APAC) region.
Su, Po-Jung
Park, Se Hoon
Tsai, Yu Chieh
Kim, Miso
Wu, Wen-Jeng
Gao, Seasea
Shin, Sang Joon
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[42] AUSTRALI-AVE: Design of a retrospective noninterventional study evaluating real-world patient characteristics and treatment patterns with avelumab in locally advanced or metastatic urothelial cancer (la/mUC) and metastatic Merkel cell carcinoma (mMCC) in Australia
Ben Tran
Moujaber, Tania
Oliveira, Niara
Shackleton, Mark
Pook, David
Franchini, Fanny
Kouhkamari, Mahsa H.
Schoeninger, Brittany
Miles, Alison G.
Wu, Beilei
Bennett, Greer
Varrasso, Annalisa
Liu, Xiao
Hoffman, Jason
Kearney, Mairead
Xu, Wen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 269 - 270
[43] Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
Aragon-Ching, J. B.
Grivas, P.
Loriot, Y.
Bellmunt, J.
Wang, J.
Michelon, E.
di Pietro, A.
Powles, T. B.
Sridhar, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1343 - S1343
[44] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) Tx: Results from IMPACT UC
Bilen, M. A.
Xi, A. D.
Wong, A.
Schroeder, A.
Kim, R.
Liu, F. X.
Peng, J.
Robinson, S.
Bhanegaonkar, A.
ANNALS OF ONCOLOGY, 2021, 32 : S713 - S713
[45] Avelumab first-line maintenance for advanced urothelial carcinoma in the phase 3 JAVELIN Bladder 100 trial: subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance
Pook, David
Sridhar, Srikala
Powles, Thomas
Loriot, Yohann
Duran, Climent Miguel
Gupta, Shilpa
Tsuchiya, Norihiko
Bamias, Aristotelis
Ardizzoni, Andrea
Ullen, Anders
Huang, Bo
Costa, Nuno
Laliberte, Robert
di Pietro, Alessandra
Sternberg, Cora
Grivas, Petros
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 43 - 44
[46] Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.
Milloy, Neil
Walley, Maria
Simpson, Amber
Forshaw, Cameron
Morris, Valerie A.
Kearney, Mairead
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[47] Avelumab first-line maintenance for advanced urothelial carcinoma (aUC) in the phase 3 JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval from end of chemotherapy to start of maintenance
Pook, David W.
Sridhar, Srikala S.
Powles, Thomas
Loriot, Yohann
Duran, Miguel A. Climent
Gupta, Shilpa
Tsuchiya, Norihiko
Bamias, Aristotelis
Ardizzoni, Andrea
Ullen, Anders
Huang, Bo
Costa, Nuno
Laliberte, Robert J.
di Pietro, Alessandra
Sternberg, Cora N.
Grivas, Petros
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 132
[48] First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel
Averbuch, Itamar
Salman, Saeed
Shtamper, Noa
Doweck, Ilana
Popovtzer, Aron
Markel, Gal
Hendler, Daniel
Finkel, Inbar
Moore, Assaf
Fenig, Eyal
Taha, Tarek
Mhameed, Kamel
Kurman, Noga
Billan, Salem
FRONTIERS IN ONCOLOGY, 2023, 13
[49] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Minmin Zhao
Shanhu Qiu
Xin Wu
Pengcheng Miao
Zhi Jiang
Tao Zhu
Xizhong Xu
Yanling Zhu
Bei Zhang
Donglan Yuan
Yang Zhang
Wei Sun
Aiqin He
Min Zhao
Wenjie Hou
Yingli Zhang
Zhuyan Shao
Meiqun Jia
Mei Li
Jun Chen
Jingcheng Xu
Bingwei Chen
Ying Zhou
Yang Shen
Targeted Oncology, 2023, 18 : 869 - 883
[50] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Zhao, Minmin
Qiu, Shanhu
Wu, Xin
Miao, Pengcheng
Jiang, Zhi
Zhu, Tao
Xu, Xizhong
Zhu, Yanling
Zhang, Bei
Yuan, Donglan
Zhang, Yang
Sun, Wei
He, Aiqin
Zhao, Min
Hou, Wenjie
Zhang, Yingli
Shao, Zhuyan
Jia, Meiqun
Li, Mei
Chen, Jun
Xu, Jingcheng
Chen, Bingwei
Zhou, Ying
Shen, Yang
TARGETED ONCOLOGY, 2023, 18 (06) : 869 - 883

← 1 2 3 4 5 →